ERC 124

Drug Profile

ERC 124

Alternative Names: Endometrial blood stem cell therapy - Intrexon; Endometrial regenerative cells; ERC-124

Latest Information Update: 03 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediStem Laboratories; Yale University
  • Developer Brigham and Womens Hospital; ERCell LLC; Intrexon Corporation; Yale University
  • Class Heart failure therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain injuries; Heart failure; Ischaemia; Peripheral vascular disorders; Type 1 diabetes mellitus

Most Recent Events

  • 03 Oct 2015 No recent reports of development identified - Clinical-Phase-Unknown for Ischaemia in China (IM)
  • 03 Oct 2015 No recent reports of development identified - Phase-II for Heart failure in Russia (Intracoronary)
  • 03 Oct 2015 No recent reports of development identified - Preclinical for Brain injuries in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top